SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ABT: Abbott Laboratories
ABT 124.51-1.7%Oct 29 3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: HerbVic who wrote (20)9/10/2003 3:37:27 PM
From: HerbVic  Read Replies (1) of 33
 
Once-Daily Depakote ER (Divalproex Sodium Extended- Release) Receives FDA Approval for Pediatric Use

-Epilepsy Drug Offers Children Age 10 and Older Convenient, Once-Daily Treatment for Complex Partial or Absence Seizures-

ABBOTT PARK, IL -- September 10, 2003 -- Abbott Laboratories announced that the U.S. Food and Drug Administration (FDA) has approved Depakote® ER (divalproex sodium extended release) tablets for sole and adjunctive therapy to treat complex partial seizures in isolation or in association with other types of seizures and simple and complex absence seizures in children, ages 10 and above, with epilepsy. Depakote ER is the once-daily formulation of Depakote(R) (divalproex sodium delayed release) tablets, which has been a leading medication for the treatment of epilepsy since its initial approval in 1983. Depakote ER was approved for migraine prevention in adults in 2000 and for epilepsy in adults in 2002.

<snip>

docguide.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News